Daptomycin in Central Nervous System Infections

Limitations of Daptomycin

The Infectious Diseases Society of America (IDSA) guidelines do not recommend daptomycin as a primary agent for CNS infections 1, 2
Daptomycin has poor penetration into the CSF, with studies showing only 5-6% penetration in inflamed meninges 2
Animal studies suggest daptomycin may sterilize CSF more rapidly and modulate CSF inflammation in pneumococcal meningitis, but human trials are lacking to support its use as an alternative to cephalosporins 3, 4

The American College of Clinical Pharmacology recommends IV vancomycin as first-line therapy for MRSA meningitis/ventriculitis, despite its poor CSF penetration of 1-5% 1, 2
Linezolid 600 mg PO/IV twice daily is an alternative option with excellent CSF penetration of up to 66% (B-II recommendation) 1, 2
For Gram-negative meningitis/ventriculitis, meropenem is the first-line therapy (drug of choice for nosocomial meningitis/ventriculitis) 5, 6

The Infectious Diseases Society of America (IDSA) recommends a treatment duration of 10 days for pneumococcal disease and 5 days for meningococcal disease 3, 4, 7
For nosocomial meningitis/ventriculitis, a 21-day course is recommended 5, 6
Monitoring of CSF sterilization through repeated cultures can help tailor the duration of therapy 5, 6

Surgical drainage of focal abscesses and removal of any foreign body should be performed whenever possible to improve treatment outcomes 1, 2
High-dose continuous infusion of antibiotics, such as vancomycin, may be considered to improve CSF penetration in patients not responding to standard dosing 2